7-Chloro-4-ethylquinoline | 135251-88-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-Chloro-4-ethylquinoline
• CAS: 135251-88-6
• 化学式: C₁₁H₁₀ClN
• 分子量: 191.66
• InChiKey: RELKYKQJELWZIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7-Chloro-4-ethylquinoline 在 二氢吡啶 、 C₅₆H₄₉O₄PSi₂ 作用下， 以 苯 为溶剂， 生成 (4R)-7-chloro-4-ethyl-1,2,3,4-tetrahydroquinoline 、 (4S)-7-chloro-4-ethyl-1,2,3,4-tetrahydroquinoline
  参考文献：
  名称：

  Direct enantioselective access to 4-substituted tetrahydroquinolines by catalytic asymmetric transfer hydrogenation of quinolines

  摘要：

  我们开发出了一种方便的对映体选择性合成 4-取代的四氢喹啉的方法。手性 BINOL 磷酸促进了范围广泛的 4-取代喹啉与汉茨赫酯的还原，对映选择性良好甚至很高。

  DOI：

  10.1039/c1ob05870c

文献信息

• UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Chen Dawei

  公开号：US20090082261A1

  公开（公告）日：2009-03-26

  The invention provides compounds urea-containing peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables T, R 1 -R 9 , J, L, M, Y, Z, m, n, and t are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain urea-containing peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more urea containing peptides compounds and one or more pharmaceutically acceptable carriers, excipients, or diluents. Such pharmaceutical compositions may contain a urea containing peptides compound as the only active agent or may contain a combination of a urea containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

  本发明提供了含有尿素的多肽化合物，其结构如式I所示，以及它们的药物盐和 hydrates（水合物）。 变量T，R1-R9，J，L，M，Y，Z，m，n和t在此文中定义。式I中的某些化合物作为抗病毒剂是有用的。本文中公开的某些含尿素的多肽化合物是病毒复制的强效和/或选择性抑制剂，尤其是丙型肝炎病毒复制。本发明还提供了包含一个或多个含尿素多肽化合物以及一个或多个药物可接受载体、辅料或稀释剂的药物组合物。这样的药物组合物可以仅含有一个含尿素多肽化合物作为唯一的活性成分，也可以包含一个含尿素多肽化合物与一个或多个其他药物活性成分的组合。本发明还提供了治疗哺乳动物中病毒感染的方法，包括丙型肝炎感染。
• PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS
  申请人：Bergmann John E.

  公开号：US20080300240A1

  公开（公告）日：2008-12-04

  Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: wherein m, n, p, x, R, R 1 , R 2 , R 3 , R 4 , R 5 , A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE 10 in a warm-blooded animal in need of the same.

  抑制PDE10的化合物已被披露，对治疗包括（但不限于）精神病、焦虑、运动障碍和/或神经系统疾病（如帕金森病、亨廷顿病、阿尔茨海默病、脑炎、恐惧症、癫痫、失语症、贝尔氏面瘫、脑瘫、睡眠障碍、疼痛、抽动症、精神分裂症、妄想症、药物诱发的精神病和恐慌以及强迫症）多种疾病具有用途。这些化合物具有一般结构： 其中m、n、p、x、R、R1、R2、R3、R4、R5、A和B在此定义，包括药学上可接受的盐、立体异构体、溶剂合物或其前药。还披露了含有本发明化合物的组合物，与药学上可接受的载体结合，以及与使用这些化合物抑制需要同样的PDE10的温血动物相关的方法。
• 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Phadke Avinash

  公开号：US20090048297A1

  公开（公告）日：2009-02-19

  The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R 1 -R 9 , R 16 , R 18 , R 19 , n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

  该发明提供了Formula I的4-氨基-4-氧代丁酰肽化合物及其药用盐和水合物。变量R1-R9、R16、R18、R19、n、M和Z在此处定义。Formula I的某些化合物可用作抗病毒剂。本文披露的某些4-氨基-4-氧代丁酰肽化合物是有效和/或选择性抑制病毒复制的药物，特别是乙型肝炎病毒的复制。该发明还提供含有一种或多种4-氨基-4-氧代丁酰肽化合物和一种或多种药用载体的药物组合物。这种药物组合物可能仅含有4-氨基-4-氧代丁酰肽化合物作为唯一活性剂，也可能含有一种或多种其他药用活性剂与含有4-氨基-4-氧代丁酰肽的肽化合物的组合。该发明还提供了治疗哺乳动物病毒感染的方法，包括乙型肝炎感染。
• [EN] PIPERIDIN-4-YLPIPERAZINE COMPOUNDS FOR THE TREATMENT OF HCV INFECTION<br/>[FR] COMPOSÉS DE PIPÉRIDIN-4-YLPIPÉRAZINE POUR LE TRAITEMENT D'UNE INFECTION À VHC
  申请人：GENOSCIENCE PHARMA

  公开号：WO2010081851A1

  公开（公告）日：2010-07-22

  The invention relates to new piperazine-pieridine compounds having anti-viral activity and particularly anti-HCV activity. The invention further relates to pharmaceutical compositions comprising compounds according to the invention.

  该发明涉及具有抗病毒活性，特别是抗丙型肝炎病毒活性的新哌嗪-哌啶化合物。该发明还涉及包含根据该发明的化合物的药物组合物。
• CYCLIC CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF AS OF HEPATITIS C VIRUS
  申请人：Zhang Suoming

  公开号：US20100124545A1

  公开（公告）日：2010-05-20

  The invention provides cyclic carboxamide compounds and analogues thereof of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R 1 , R 6 -R 8 , R 16 , R 18 , R 19 , M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain cyclic carboxamide compounds and cyclic carboxamide analogues disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more cyclic carboxamide compounds or cyclic carboxamide analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a cyclic carboxamide compound or cyclic carboxamide analogue as the only active agent or may contain a combination of a cyclic carboxamide compound or cyclic carboxamide analogue and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.

  本发明提供了公式I的环状羧酰胺化合物及其类似物，以及其药物盐和水合物。其中，变量R、R1、R6-R8、R16、R18、R19、M、n、T、Y和Z在此定义。公式I的某些化合物可用作抗病毒剂。本发明所披露的某些环状羧酰胺化合物和环状羧酰胺类似物是有效和/或选择性抑制病毒复制的抑制剂，尤其是乙型肝炎病毒复制的抑制剂。本发明还提供了含有一个或多个环状羧酰胺化合物或环状羧酰胺类似物和一个或多个药用载体的药物组合物。这样的药物组合物可以仅包含一个环状羧酰胺化合物或环状羧酰胺类似物作为唯一活性剂，也可以包含一个环状羧酰胺化合物或环状羧酰胺类似物和一个或多个其他药用活性剂的组合。本发明还提供了治疗病毒感染，包括乙型肝炎感染的方法。